Neuroendocrine tumors (NETs) of the pancreas, also called pancreatic neuroendocrine tumors (PNETs), are a rare and diverse group of cancers that arise from the hormone-producing cells of the pancreas. These tumors can be functional, producing excess hormones that cause distinct clinical syndromes, or non-functional, often detected later due to mass effects or metastasis. PNETs are typically classified into stages based on their size, extent of local invasion, lymph node involvement, and presence of distant metastases. In Stage I, tumors are small and confined to the pancreas without lymph node involvement. Stage II involves larger tumors or local extension beyond the pancreas but still without distant spread. Stage III indicates regional lymph node involvement or further local invasion, while Stage IV describes tumors that have metastasized to distant organs such as the liver. The staging is critical for guiding treatment decisions and prognosis, as early-stage tumors may be treated effectively with surgery, whereas advanced stages often require systemic therapies.

Pancreatic neuroendocrine tumors (PNETs) are influenced by a variety of risk factors, with genetic predisposition playing a central role. Inherited syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1), von Hippel-Lindau disease (VHL), neurofibromatosis type 1 (NF1), and tuberous sclerosis complex (TSC) significantly increase the likelihood of developing PNETs by causing mutations that promote tumor growth in endocrine tissues. Apart from these well-characterized syndromes, having a family history of neuroendocrine tumors or endocrine cancers may also elevate risk, suggesting possible yet unidentified genetic contributions. Age is another important factor, as PNETs are most commonly diagnosed in individuals between 40 and 60 years old, although they can occur at any age. While lifestyle factors like smoking and alcohol consumption are major risks for pancreatic adenocarcinoma, their association with PNETs is less clear and appears to be minimal. Chronic medical conditions such as long-standing diabetes and chronic pancreatitis have been investigated for possible links to PNETs, with some evidence suggesting that prolonged inflammation or metabolic disturbance could contribute to tumor development, though these connections require further validation.

Pancreatic neuroendocrine tumors (PNETs) can present with a wide range of symptoms, which largely depend on whether the tumor is functional (hormone-secreting) or non-functional. Functional PNETs produce excess hormones that cause specific clinical syndromes: for example, insulinomas secrete insulin, leading to symptoms of low blood sugar such as sweating, confusion, weakness, and fainting; gastrinomas produce excess gastrin, causing severe stomach ulcers and abdominal pain (Zollinger-Ellison syndrome); and glucagonomas result in high blood sugar and a characteristic skin rash. Non-functional PNETs, which do not secrete hormones, often remain asymptomatic until they grow large enough to cause symptoms related to the tumors size or spread. These may include abdominal pain, a palpable mass, unexplained weight loss, nausea, vomiting, or jaundice if the tumor compresses the bile duct. Because symptoms can be vague or related to hormone effects, diagnosis is often delayed, especially for non-functional tumors, which may only be detected incidentally during imaging for other reasons or when metastasis has occurred.

Diagnosis of pancreatic neuroendocrine tumors (PNETs) involves a combination of clinical evaluation, biochemical testing, and imaging studies. Initially, if a functional tumor is suspected based on symptoms, blood and urine tests are performed to measure hormone levels such as insulin, gastrin, glucagon, or vasoactive intestinal peptide (VIP), depending on the suspected tumor type. Chromogranin A, a general tumor marker for neuroendocrine tumors, is also commonly measured but is not specific. Imaging plays a critical role in locating the tumor and assessing its extent; techniques include contrast-enhanced computed tomography (CT) scans and magnetic resonance imaging (MRI), which help identify the size and spread of the tumor. Functional imaging with somatostatin receptor scintigraphy (Octreoscan) or positron emission tomography (PET) using gallium-68 DOTATATE is especially useful for detecting tumors that express somatostatin receptors and can reveal both primary and metastatic sites. Endoscopic ultrasound (EUS) may be employed to obtain fine-needle biopsies for histological diagnosis and grading of tumor aggressiveness. Together, these diagnostic tools guide staging, treatment planning, and prognosis.

Treatment of pancreatic neuroendocrine tumors (PNETs) depends on the tumors size, stage, functionality, and whether it has spread. For localized tumors, surgical removal is the mainstay of treatment and offers the best chance for cure, often involving removal of the tumor along with affected lymph nodes. In cases where tumors are functional, surgery can also help control hormone-related symptoms. For advanced or metastatic PNETs, medical therapies are used to control tumor growth and symptoms. Somatostatin analogs (such as octreotide and lanreotide) are commonly used to reduce hormone secretion and slow tumor progression. Targeted therapies like mTOR inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib) have demonstrated effectiveness in controlling tumor growth in some patients. Peptide receptor radionuclide therapy (PRRT) is an emerging treatment that delivers targeted radiation to tumor cells expressing somatostatin receptors, showing promising results especially in metastatic cases. Chemotherapy may be considered for more aggressive or rapidly progressing tumors. Additionally, supportive care to manage symptoms such as pain, hormone imbalance, and nutritional issues is an important part of comprehensive treatment. Treatment plans are often individualized, guided by tumor characteristics, patient health, and response to therapy.

Reducing the risk of pancreatic neuroendocrine tumors (PNETs) can be challenging, especially since many cases arise sporadically without clear preventable causes. However, for individuals with known genetic syndromes like MEN1, von Hippel-Lindau, or neurofibromatosis, regular surveillance through biochemical testing and imaging can help detect tumors early, improving outcomes. Maintaining a healthy lifestyle-such as avoiding tobacco use, limiting alcohol consumption, managing chronic conditions like diabetes, and maintaining a healthy weight-may support overall pancreatic health, although direct links to PNET prevention are not well established. For those with a family history or genetic predisposition, genetic counseling and testing are important to assess risk and guide early monitoring strategies. While specific lifestyle changes have not been proven to prevent PNETs directly, early detection through vigilance and routine medical follow-up remains the most effective approach to reduce the impact of these tumors.

Ongoing research in pancreatic neuroendocrine tumors (PNETs) is focused on improving diagnosis and treatment through advanced imaging techniques, targeted therapies, and novel immunotherapies. One promising development is the CECT-Mamba model, which enhances the accuracy of tumor subtyping using contrast-enhanced CT scans, helping distinguish PNETs from other pancreatic cancers with over 97% accuracy. Clinical trials are also exploring combination treatments such as Lutetium Lu 177 Dotatate paired with triapine or fulvestrant to improve outcomes in advanced cases. Additionally, innovative immunotherapy approaches, including an experimental cancer vaccine called ELI-002 2P, have shown encouraging results by stimulating immune responses against tumors with KRAS mutations, potentially preventing cancer recurrence.

1. What are pancreatic neuroendocrine tumors (PNETs)? PNETs are rare tumors arising from hormone-producing cells in the pancreas. They can be functioning (secreting hormones causing symptoms) or non-functioning (no hormone symptoms). Their behavior ranges from slow-growing to aggressive. 2. How common are pancreatic NETs? PNETs are uncommon, making up about 1-2% of all pancreatic tumors. Improved imaging has increased diagnosis rates, often detecting tumors incidentally. 3. Are pancreatic NETs curable? Yes, if caught early, surgery can cure many pancreatic NETs. Advanced cases may require treatments like targeted therapy, chemotherapy, or hormone-blocking drugs to control tumor growth and symptoms. 4. What are the survival rates for pancreatic NETs? Survival depends on stage and tumor type. Early-stage PNETs have 5-year survival rates of 60-90%, while advanced metastatic disease has lower survival, though targeted therapies have improved outcomes. 5. What symptoms do pancreatic NETs cause? Symptoms vary. Functioning tumors cause hormone-related symptoms like low blood sugar, stomach ulcers, or diarrhea. Non-functioning tumors often cause vague symptoms like abdominal pain or are found incidentally on scans.